Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKeyur P. PatelJGJanamejey Gaur

Discussion

Loading...

Member takes

Overview

Systematic review shows hypomethylating agents may offer limited control, while allogeneic transplant suggests higher survival rates in high-risk MDS patients.

Key Points

  • Immediate allogeneic transplant nearly doubles 3- to 5-year survival rates compared to hypomethylating agents alone.
  • Survival advantage seen in 3-year overall survival, reaching 47.9% with donor versus 26.6% without.
  • Systematic review assesses nine studies comparing transplant to non-transplant therapies for high-risk MDS.
  • Patient age should not preclude transplant; delays in HSCT worsen outcomes significantly.

Cite This Study

Patel et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfd7https://doi.org/10.1182/blood-2025-7369
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes2025
  2. 2Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification2025
  3. 3Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT2025
  4. 4Impacts of IPSS-m and conditioning intensity in allogeneic hematopoietic cell transplant for patients with myelodysplasia neoplasms2025
  5. 5Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes2025 · 1 citations